AstraZeneca PLC (AZN)
AZN trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), period ending 2025-12-31, https://www.sec.gov/Archives/edgar/data/901832/000110465926019130/0001104659-26-019130-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), period ending 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | AZN on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United Kingdom |
| IPO year | 2026 |
| SEC CIK | 0000901832 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | X0 |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $58.7B |
| Net income | $10.2B |
| Operating income | Not in SEC XBRL data |
| Net margin | 17.4% |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | Not in SEC XBRL data |
| Total assets | Not in SEC XBRL data |
| P/E (computed) | 23.6× |
| P/S (computed) | 4.1× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B2 | 2026-02-27 |
| Latest annual report | 20-F | 2026-02-24 |
| Latest quarterly / interim ASTRAZENECA COMPLETES EQUITY INVESTMENT IN SUMMIT | 6-K | 2026-10-05 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +1.2% |
| 1 month | +0.1% |
| 3 months | -4.3% |
| Year to date | -11.9% |
| 1 year | -4.1% |
| From 52-week high | -22.7% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| NVS | Novartis AG | $142.41 | -0.99% | $271.7B |
| ABT | Abbott Laboratories | $102.61 | +0.78% | $177.6B |
| NVO | Novo Nordisk A/S | $38.06 | -1.35% | $168.5B |
| MRK | Merck & Company Inc. Common Stock (new) | $141.98 | -2.39% | $350.3B |
| PFE | Pfizer Inc. | $28.37 | -0.11% | $161.7B |
| VRTX | Vertex Pharmaceuticals Incorporated | $485.22 | -4.30% | $123.0B |
| ABBV | AbbVie Inc. | $274.36 | -2.40% | $484.8B |
| BMY | Bristol-Myers Squibb Company | $56.67 | -1.58% | $115.8B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier